Primary Institution:Icahn School of Medicine at Mount Sinai
Current SEPA Project
Dr. Florian Krammer received his advanced training in biotechnology and applied virology at the University of Natural Resources and Life Sciences, Vienna (Mentor: Dr. Reingard Grabherr), where he gained extensive experience with expression and purification of recombinant (glyco-) proteins and influenza virus-like particles. He established various expression systems for these proteins using insect cells/baculovirus, mammalian cells, bacteria, yeast and plants. Furthermore, he worked on a novel influenza virus rescue system based on baculovirus transduction of mammalian cells and a novel bioassay to measure inhibition of the influenza virus polymerase complex by cap-snatching inhibitors. He graduated from the University of Natural Resources and Life Sciences, Vienna in 2010. Prof. Krammer’s post-doctoral work in the laboratory of Dr. Peter Palese at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York focused on the development of broadly neutralizing anti-hemagglutinin stalk antibodies and the design of an universal influenza virus vaccine. The results of these studies have been very promising: After successful testing in animal models (mice, ferrets), studies with this universal influenza virus vaccine are now advancing to human clinical trials. Currently Prof. Krammer holds a position as a Professor of Vaccinology at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. He has published more than 100 papers, is member of the editorial boards of the Journal of Virology, Plos One and Heliyon and is a peer reviewer for more than 30 journals. Dr. Krammer is also member of the Vaccine and Edward Jenner Society Young Investigator Program. In addition he is a scientific adviser for enGenes and PathSensors. Since 2019, Prof. Krammer is the Principal Investigator of the Sinai-Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC). Our CIVIC aims to develop improved seasonal and universal influenza virus vaccines that induce long lasting protection against drifted seasonal, zoonotic and future pandemic influenza viruses. The Krammer laboratory focuses on understanding broadly-reactive immune responses against the surface glycoproteins of RNA viruses such as influenza with the goal to develop better vaccines and novel therapeutics.